Targeting drug delivery and the small airways in asthma.
This year will see the launch of the first chlorofluorocarbon (CFC)-free formulation of beclomethasone. Developed by 3M Health Care, its extrafine formulation gives significant benefits resulting from increased lung deposition and improved inhaler technology. Its difference from CFC-propelled inhalers is so marked that it will challenge views about about the risk-benefit profile of beclomethasone.
Williams
A
A
Department of Thoracic Medicine, Royal Bournemouth Hospital.
D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D001980:Bronchi / Q000187:drug effects; D006801:Humans; D009330:Nebulizers and Vaporizers
D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents; D001507:Beclomethasone